- WuXi Biologics is expanding its drug product (DP) capabilities at its Leverkusen, Germany facility by adding a new sterile filling line for prefilled syringes (PFS).
- The new line will enable flexible GMP production of 17 million syringes annually, with construction set to be completed by 2026.
WuXi Biologics, a global Contract Research, Development, and Manufacturing Organization (CRDMO), has announced plans to enhance its drug product (DP) capabilities at its Leverkusen, Germany facility. The company will add a new sterile filling line for prefilled syringes (PFS) using isolator technology, aimed at increasing production capacity and supporting growing client demand.
The new sterile filling line, designed to handle syringe sizes of 1 ml, 2.25 ml, and 3 ml, will have a filling rate of up to 400 syringes per minute. This upgrade will boost the facility’s production capacity to 17 million syringes per year, complementing the existing freeze-drying and sterile filling line, which has an annual capacity of approximately 10 million doses. The new line’s construction will begin soon, with plans to achieve GMP compliance by 2026.
Dr. Chris Chen, CEO of WuXi Biologics, explained, “The increased capacity in Germany will allow us to continue to meet growing client demand for DP services, especially for prefilled syringes.” He further emphasized that this investment supports the company’s Global Dual Sourcing strategy, allowing the company to provide flexible manufacturing capabilities across its global network.
This new facility expansion reflects WuXi Biologics’ continued commitment to supporting the global healthcare industry by providing efficient and cost-effective manufacturing solutions. The enhanced capacity will help meet the increasing demand for biologic drug products, particularly prefilled syringes, and contribute to the company’s ongoing role as a trusted partner in the pharmaceutical sector.
Overview of outsourcing trends 
